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Research Highlights: 
• Refined mouse reduced uterine perfusion pressure (mRUPP) model exhibits 
preeclampsia symptoms 
• Mouse RUPP induces maternal hypertension, kidney injury, elevates circulating 
sFlt-1 levels and promotes nitrosative stress 
• Mouse RUPP reduces expression of the protective enzyme, placental cystathionine 
γ-lyase and causes poor fetal outcome 
• H2S releasing aspirin, MZe786, acts as an inhibitor of sFlt-1 to successfully prevent 
preeclampsia and improve fetal outcome  
• MZe786 is a novel drug with therapeutic potential to prevent preeclampsia 
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Abstract 
An imbalance in angiogenic growth factors and poor utero-placental perfusion are strongly 
associated with preeclampsia. The reduced utero-placental perfusion (RUPP) model that 
mimics insufficient placental perfusion is used to study preeclampsia. The aim of this study 
was to develop a refined RUPP model in C57Bl/6J mice to test the efficacy of MZe786 as 
a potential inhibitor of soluble Flt-1 for preeclampsia therapy. Murine RUPP was induced 
through bilateral ligation of the ovarian arteries at E11.5 that resulted in typical 
preeclampsia symptoms including increase in mean arterial pressure (MAP), kidney injury 
and elevated soluble Flt-1 (sFlt-1) levels in the maternal plasma and amniotic fluid. The 
murine RUPP kidneys showed tubular and glomerular damage along with increased 
oxidative stress characterised by increased nitrotyrosine staining. The mRUPP displayed 
abnormal placental vascular histology, reduced expression of placental cystathionine γ-
lyase (CSE), the hydrogen sulfide (H2S) producing enzyme, and resulted in adverse fetal 
outcomes (FGR). Importantly, oral administration of hydrogen sulfide (H2S)-releasing 
compound MZe786 from E11.5 to E17.5 successfully prevented the development of 
preeclampsia. Specifically, MZe786 treatment reduced maternal MAP and kidney 
nitrotyrosine staining and improved fetal outcome. The circulation levels of sFlt-1 were 
dramatically decreased in MZe786 treated animals implying that H2S released from 
MZe786 offered protection by inhibiting sFlt-1 levels. MZe786 prevent preeclampsia and 
warrant a rapid move to randomise control clinical trial.  
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Introduction 
Preeclampsia is characterised by new hypertension along with complications affecting 
maternal organs and the feto-placental systems (1, 2). It contributes significantly to poor 
health outcomes in later life for both the mother and the baby (3-5). Ten to 30 years after 
preeclampsia, women are several folds higher risk of developing high blood pressure, 
heart disease, chronic heart failure and stroke (6). Despite a better understanding of the 
disease mechanism (7-12), effective pharmacological therapeutics has yet to be identified. 
Unfortunately, the only option available today is the early delivery of the baby with all the 
negative consequences associated with it.  
Circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1), the natural inhibitor of 
vascular endothelial growth factor (VEGF), is elevated before the clinical onset of 
preeclampsia (12). Although this disease is almost unique to humans and higher primates 
(13), several animal models have been developed to mimic symptoms of preeclampsia. 
The reduced utero-placental perfusion (RUPP) procedure was first performed in female 
baboons and guinea-pigs and resulted in hypertension and proteinuria during pregnancy 
(14, 15). Granger and colleagues modified the RUPP technique in rats with reduction of 
blood flow in abdominal aorta and uterine arteries (16-18).  
The first direct evidence that a dysfunctional cystathionine γ-lyase (CSE) / hydrogen 
sulfide (H2S) pathway contributes to the pathogenesis of preeclampsia (7) was 
demonstrated using CSE inhibition, which induced preeclampsia-like features in pregnant 
mice owing to the inhibition of H2S production. Intraperitoneal injection of a slow-releasing 
H2S-generating compound GYY4137 restored fetal growth and reduced sFlt-1 levels in 
pregnant animals (7).  
Here we report a refined mouse RUPP (mRUPP) model in a common inbred strain of 
C57Bl/6J mice, which caused an increase in sFlt-1 levels, induced hypertension, kidney 
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damage, altered placental morphology and adverse fetal outcome. Importantly, we 
demonstrate the successful use of this model to test the efficacy of an orally active H2S-
releasing MZe786 to inhibit sFlt-1 and reversed the clinical characteristics of preeclampsia.  
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Materials and Methods 
For detailed descriptions of the materials and methods used, please see Supplementary 
file. 
Materials 
The H2S-releasing molecule, MZe786 (2-acetyloxybenzoic acid 4-(3-thioxo-3H-1,2-dithiol-
5-yl)phenyl ester) also known as ACS14, with a defined pharmacological profile, was used 
as previously described (19-21). 
Methods 
Refined Murine Reduced Uterine Perfusion Pressure (mRUPP) model 
Twelve to twenty-week-old C57Bl/6J males were mated with similar aged C57Bl/6J female 
mice. The first day of pregnancy (E0.5) was defined by the presence of vaginal plug the 
following morning. At E11.5, pregnant mice were anesthetised with 2% isoflurane. 
Abdominal cavity was opened by an incision through the linea alba. Using magnetic 
retractors, the skin and muscle was gently pulled for a better visual of the organs and pups 
of the mice. The ovarian arteries on either side were identified and ligated above the 
ovaries using 7-0 silk sutures (Fig. 1B). The incisions were closed using Vicryl 6.0 sutures. 
Sham control group underwent comparative manipulations but without ovarian artery 
ligation. All surgeries were carried out under aseptic conditions and buprenorphine 
(0.05mg/kg) i.p was administered for 48 hours post-surgery. mRUPP and Sham were 
either treated with drug carrier (0.5% carboxymethyl cellulose in PBS) or 50mg/kg of 
MZe786 from E11.5 to E17.5 via gavage. On E16.5, mice were placed in metabolic cages 
to collect urine for 24 hours. On day E17.5 the mice were sacrificed, and the tissues were 
harvested. 
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Acute blood flow assessment 
The blood flow in the ovarian artery was assessed using laser Doppler flowmetry (LDF) on 
mRUPP pre- and post-ligation as perversely described (22).  
Blood pressure analysis 
Blood pressure was measured on E17.5 as described previously (7).  
Enzyme-Linked Immunosorbent Assay  
Enzyme-linked immunosorbent assay kits for murine sFlt-1 and KIM-1 were obtained from 
R&D Systems, UK and assays performed according to the manufacturer’s specifications. 
Immunohistochemistry 
Murine kidney and placental tissue sections were prepared for immunohistochemistry as 
previously described (23).  
Histological analysis 
Murine kidney and placental tissues were embedded with paraffin and stained for 
Hematoxylin and eosin (H&E). H&E stained kidney and placenta tissues were imaged 
using NanoZoomer (Hamamatsu, Japan). Area of the labyrinth zone was measured and 
analysed using ImageJ. Kidney analysis was done in a semi-quantitative manner as 
described previously (24, 25). Two researchers performed independently the analysis of 
placenta and kidney blindly. 
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Statistical analysis 
Data is presented as either mean and SEM or median and range as appropriate. 
Comparison between two groups was performed using Mann-Whitney U-test (non-
parametric). Comparisons among three or more groups were performed using Two-way 
ANOVA. Statistical significance was set at p<0.05. 
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Results 
Refined mRUPP model in C57Bl/6J mice. We used C57Bl/6J mice to develop a refined 
mRUPP model that could successfully mimic appropriate clinical and biochemical signs of 
preeclampsia. In contrast to the traditional method of ligating abdominal aorta and ovarian 
artery, we performed surgical occlusion of ovarian arteries on either side (Fig. 1B). 
Importantly the surgery was performed much earlier into pregnancy (E11.5) compared to 
the traditional method (E14.5), providing a longer ‘therapeutic window’ (Fig. 1A). Laser 
Doppler blood flow measurements showed that the ligation of ovarian arteries proximal to 
ovaries significantly reduced arterial flow post-ligation (Fig. 1C). The flow rate in the 
abdominal aorta remained unchanged (Supplementary Fig. 1C) by this procedure.  
MZe786 improved maternal outcome in mRUPP. Mice that underwent mRUPP surgery 
showed typical preeclamptic features such as high mean arterial blood pressure compared 
to Sham operated mice (Fig. 2A). In humans, preeclampsia affect kidney function during 
pregnancy with a four-fold increased risk of developing end-stage renal disease within 10 
years after pregnancy (26). Semi-quantitative, blinded evaluation of kidney histology 
revealed histopathological alterations in the mRUPP kidneys such as glomerular 
degeneration, narrowing or disappearance of Bowman’s space, tubular atrophy, fibrosis 
and vascular congestion (Fig. 2B and C). The size of glomeruli in mRUPP group appeared 
smaller compared to Sham and did not reach statistical significance (Supplementary Fig. 
2A). Likewise, the renal artery wall appeared to be thicker in mRUPPs compared to Sham 
and again was not statistically significant (Supplementary Fig. 2B). The levels of Kidney 
Injury Marker (KIM-1) in urine were significantly increased in mRUPP mice confirming the 
renal injury in this model (Fig. 2D). We have previously shown evidence that preeclampsia 
is associated with reduced circulating levels of H2S (7). Here we show that oral 
administration of H2S releasing molecule, MZe786 significantly improve maternal outcome 
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in the mRUPP model. Specifically, the mean arterial blood pressure was significantly 
reduced in MZe786 treated mRUPPs (Fig. 2A). Two doses of MZe786 were tested, 
25mg/kg and 50mg/kg. 25mg/kg of MZe786 did not reduce blood pressure in mRUPPs 
(Supplementary Fig. 3). Hence, 50mg/kg dose was selected for future studies. The 
mRUPP/Sham mice that received drug carrier (orally) were used as controls. MZe786 also 
significantly improved the renal injury induced by mRUPP as evidenced by reduced kidney 
damage score (Fig. 2B and C) and reduced KIM-1 levels in urine (Fig. 2D). The mRUPP 
kidneys showed higher oxidative stress as evidenced from increased nitrotyrosine staining 
compared to Sham (Fig. 3A, B). Importantly, MZe786 effectively suppressed oxidative 
stress as evidenced from marked reduction in nitrotyrosine staining in the treated group 
(Fig. 3A and B).  
 
MZe786 rescue fetal outcome in mRUPP. The percentage of viable fetuses was 
significantly lower in mRUPP compared to Sham (Fig. 4A and B). H2S releasing molecule 
MZe786, significantly increased the live birth percentage in mRUPP (Fig. 4A and B). The 
mouse placenta is comprised of three distinct zones; the maternally derived decidua, and 
the conceptus-derived junctional and labyrinth zones. The labyrinth zone consist of two 
layers of multinucleated syncytiotrophoblast (SynT) cells resulting in a large surface area 
for nutrient and gas exchange between mother and fetus (27). Blinded histological analysis 
of placental sections showed that the area of labyrinth zone was significantly reduced in 
mRUPP compared to Sham (Fig. 5A and C). This reduction was reversed successfully by 
oral administration of MZe786 (Fig. 5A and C). In mature placenta, fetal-derived 
endothelial cells line the maternal blood spaces (28). Using isolectin B4 to highlight the 
fetal endothelial cells (7), we compared the anatomic features of labyrinth zone in Sham, 
mRUPP and MZe786 treatment groups. In control mice, the labyrinth showed organised 
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fetal vessels with well-developed branching morphogenesis (Fig. 5B). The mRUPP 
placentas showed irregular branching. More importantly, MZe786 treatment group showed 
organised fetal vessels similar to Sham (Fig. 5B). 
 
MZe786 rescue preeclampsia phenotype by suppressing sFlt-1 in mother and fetus.  
Soluble Flt-1 is the anti-angiogenic factor with the highest strength of association with 
preeclampsia; elevated levels of sFlt-1 are reported in plasma (29), placenta (12) and 
amniotic fluid (30) of preeclamptic women. Previous study from Ahmed’s laboratory 
demonstrated that endothelial knockdown of CSE resulted in increased release of sFlt-1 
(7). We investigated whether similar changes in levels of sFlt-1 occur in the refined 
mRUPP model in which we also observed decreased placental expression of CSE 
following RUPP surgery (Fig. 6A). Expression levels of sFlt-1 were significantly increased 
in placental tissue (Fig. 6B) and amniotic fluid (Fig. 6C) in mRUPP. The maternal sFlt-1 
levels were 3-fold higher in mRUPP compared to Sham controls (Fig. 6D). In contrast, 
circulating VEGF levels remained unchanged (Supplementary Figure 4). To determine 
whether MZe786 inhibits sFlt-1 release, we assessed sFlt-1 levels in pregnant mice 
treated with MZe786. In mRUPP, MZe786 effectively reduced the sFlt-1 levels to Sham 
control levels (Fig. 6D). The levels of sFlt-1 in amniotic fluid (Fig. 6C) and placenta 
expression of sFlt-1 mRNA were (Fig. 6B) were also significantly decreased compared to 
mice that received drug carrier as control. 
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Discussion 
We recently reported that MZe786 rescues mitochondrial activity by stimulating cardiac 
mitochondrial biogenesis and antioxidant defence in heme oxygenase-1 deficient mice 
under high sFlt-1 environment (19). With a good safety profile, MZe786 was a good H2S 
releasing candidate for testing in an animal model of preeclampsia (20). The beneficial role 
of MZe786 has been reported in atherosclerosis (31) and is shown to have strong 
antithrombotic effect (32). Here we report the development of a refined RUPP model in 
mice and demonstrate the clear beneficial effect of MZe786 in rescuing preeclampsia 
symptoms and suppressing maternal and placental sFlt-1 levels. Acute kidney injury is 
commonly associated with preeclampsia and have high rates of associated maternal and 
perinatal mortality (33). Consistent with the high KIM-1 levels in the urine of mRUPP 
pregnancy, the kidneys showed renal damage including tubular and glomerular 
degeneration, fibrosis and vascular congestion. MZe786 suppressed KIM-1 and improved 
renal histology. 
A common complication of hindlimb ischemia that can lead to complete paraplegia is due 
to restriction of abdominal aorta in the rat RUPP model (34) indicating that aortic restriction 
occludes blood flow to the entire hindquarters of the animal. Hence, the symptoms of 
preeclampsia observed in these animals cannot be classified as specific to insufficient 
uteroplacental perfusion. Attempts to improve the model by restricting the blood flow 
specifically to the uteroplacental units in rats resulted in increased blood pressure. 
However, many of the prominent features of preeclampsia including elevated sFlt-1 levels 
and renal damage were absent (35, 36).  An earlier report of RUPP in C57Bl/6J mice used 
restriction of abdominal aorta and ovarian arteries making the preeclamptic symptoms 
unspecific to uteroplacental perfusion (18). The study showed increased blood pressure 
and serum sFlt-1 levels, but placental sFlt-1 expression remain unchanged and kidney 
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damage was absent (18). In the present study, by ligating the ovarian arteries only, we 
avoided interfering with the abdominal blood flow (Supplementary Fig. 1). Fushima et al in 
an earlier study had shown that the positional effect of ligation of the vascular arcade (37). 
They bilaterally ligated ovarian vessels distal to ovarian branches, uterine vessels, or both 
in an outbred strain of mice at E14.5. The study showed increased blood pressure, 
glomerular endotheliosis and reduction in pup weights post-surgery (37). However, the 
important feature of increased maternal plasma sFlt-1 levels and placental expression of 
sFlt-1 were absent, which is a major component of preeclampsia. Importantly, we have 
performed the surgery earlier at E11.5 in C57Bl/6J, which corresponds to the beginning of 
the second trimester of mouse pregnancy and approximately similar in gestation period 
when preeclampsia develops in women. This has allowed us to increase the therapeutic 
window for testing drugs. All other RUPP models reported so far have performed surgery 
at a later day of E14.5, when placentation is fully established.  
E11.5 is a crucial time when placentation develops. This study reports marked 
pathophysiological changes in the placenta of RUPP pregnancy. There was significant 
reduction in placental labyrinth zone in mRUPP pregnancy, which is a crucial site for 
nutrient and gas exchange between mother and fetus. The labyrinth zone also showed 
marked anatomical changes with disorganised fetal vessels. Typical features such as 
blood pressure, sFlt-1 levels were significantly higher in mRUPPs compared to Sham 
controls.  
Performing the surgery at E11.5 also gives a good ‘therapeutic window’. The protective 
effect of H2S has been widely reported in cardiovascular (38-41), neurodegenerative 
diseases (42, 43) and in multiple cancer pathophysiology (44-46). In this study, we used 
MZe786, which is a H2S releasing aspirin as a source of H2S. Chronic use of aspirin is 
frequently associated with gastropathy, partly due to, redox imbalances (47). MZe786 has 
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been shown to counter the redox imbalance processes through increased H2S/glutathione 
production, heme oxygenase-1 promoter activity and by suppression of 8-isoprostane-
prostaglandin F2α (8-isoprostane) formation (20). MZe786 has been shown to effectively 
reverse pathological symptoms in a rat model of metabolic syndrome (48). The study 
compared the effect of MZe786 with its parent compound aspirin and confirmed the clear 
beneficial effect of MZe786 over aspirin (21, 48). Since the clear beneficial role of MZe786 
over aspirin was already established, we chose not to include an aspirin-only group to 
minimise animal usage, as our objective was to see if MZe786 reduced sFlt-1 levels. 
Aspirin was reported not to inhibit sFlt-1 (49). Primarily, the mode of action of MZe786 
involves H2S release. The H2S release profile of MZe786 shows a significant early 
increase in circulating H2S and the administration of MZe786 also increases Cysteine and 
GSH levels in the kidneys (20, 50). H2S is reported to act as a relaxing factor for blood 
vessels by altering K+ channel activity and cGMP levels in vascular smooth muscle cells 
(51, 52). In agreement, we saw reduced blood pressure in mRUPP mice treated with 
MZe786. MZe786 successfully reduced KIM-1 levels and prevented kidney damage. The 
mRUPP kidneys showed increased nitrotyrosine staining indicating the presence of excess 
peroxynitrate, which is known to alter mitochondrial function to generate free radicals. 
Endothelial nitric oxide is regulated by VEGF (53). In preeclampsia, the abnormally high 
sFlt-1 levels is responsible for reduced VEGF activity (54). This may explain the 
dysregulation of intracellular NO and superoxide and the resultant production of excess 
peroxynitrate (55). Importantly, MZe786 significantly reduced nitrotyrosine staining in 
kidneys.  
Notably, MZe786 administration was found to ameliorate placental structural alterations as 
indicated by increased labyrinth zone compared to mRUPPs. Increase in labyrinth zone 
area has been associated with a positive adaptation of placenta for better nourishment of 
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fetus in mice (56). Importantly, MZe786 improved fetal outcome in mRUPPs as evidenced 
by increase in viable fetuses and more organised fetal vasculature. 
Angiogenic imbalance caused by increased circulation of sFlt-1 is highlighted as a prime 
culprit in preeclampsia contributing to most of the preeclamptic symptoms. Hence any 
intervention that would reduce the elevated levels of sFlt-1 may improve pregnancy 
outcome and protect the mother from permanent vascular damage. We have previously 
shown that dysregulation of H2S by inhibition of CSE increase sFlt-1 release (7). Surgically 
induced preeclampsia consistently showed increased maternal and fetal expression levels 
of sFlt-1 and marked reduction in the placental expression of CSE. Our recent studies 
have shown that CSE/H2S pathway sustain endothelial mitochondrial bioenergetics and 
loss of CSE increased the production of mitochondrial-specific superoxide (19). 
Mitochondria are the main source of reactive oxygen species during ischemia in renal 
tissue (57). A key regulator of reactive oxygen species detoxification and oxidative 
phosphorylation is the nuclear transcriptional co-activator peroxisome proliferator-activated 
receptor co-activator (PGC)-1α (58). Previous reports show reduced expression of PGC-
1α in renal tissue from RUPP rats (59). PGC-1α is also a master regulator of mitochondrial 
biogenesis signals (60). We recently demonstrated the ability of MZe786 to rescue 
mitochondrial biogenesis and anti-oxidant defence in heme oxygenase-1 deficient mice 
exposed to a high sFlt-1 environment (19). Here we show that MZe786 successfully 
reduced maternal and fetal sFlt-1 levels and reduced oxidative stress in mRUPP kidneys 
as evidenced by decreased nitrotyrosine staining. The administration H2S-releasing 
molecules have previously shown to protect against oxidative stress in models of unilateral 
ureteric obstruction induced renal injury (61) and bilateral renal ischemia in rats (62). H2S 
treatment protects the mitochondrial health by reducing apoptosis, mitochondrial swelling 
and loss of mitochondrial integrity induced by renal ischemia/reperfusion injury in rats (63). 
MZe786 suppressed the increase sFlt-1 that was a likely result of decreased CSE 
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expression in the mRUPP model. As observed in our earlier publications (19), this was 
probably due in part to the increased expression of the antioxidant genes and improved 
mitochondrial biogenesis that suppressed oxidative stress.  
 In conclusion, the development of this refined surgically induced model of preeclampsia 
that captures major preeclampsia features including up-regulation of sFlt-1 and down-
regulation of protective enzymes offers a unique opportunity to test novel therapeutics for 
the prevention of preeclampsia. MZe786 significantly limited the development of 
preeclampsia in the mRUPP model by suppressing sFlt-1 and nitrosative stress as well as 
improving antioxidant genes (21) and cellular mitochondrial function (64, 65). This 
compound warrants urgent investigation in clinical settings.  
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Table 1. Severity grading used to assess kidney damage score. 
 
Score 0 1 2 3 4 5 
% of area 
affected 
No change 0-10% 10-25% 25-50% 50-75% >75% 
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Figure Legends 
Figure 1. Refined RUPP model in C57Bl6/J mice. (A) Diagram illustrates the 
experimental protocol for mRUPP mouse model. Female C57B16/J were time mated with 
similar aged males and on E11.5 of pregnancy RUPP/Sham surgery was performed. The 
mice were then divided into groups to receive 50mg/kg of MZe786 orally daily from E11.5 
to E17.5. Control mice received drug career (0.5% carboxymethyl cellulose in PBS). All 
mice were harvested on E17.5 (B) Schematic representation of mouse uterus showing 
placement of ligation in the ovarian arteries. (C) Blood flow rate in the ovarian artery at 
base line (pre-mRUPP) and after RUPP surgery (post-mRUPP). The blood flow rate was 
significantly decreased post ligation. Data expressed as mean (±SEM) and analysed by 
non-parametric t-test, n=7. 
 
Figure 2. H2S-releasing molecule, MZe786 rescued preeclamptic phenotype in 
mRUPP model. (A) Mean arterial blood pressure (MAP) recorded at day 17.5 of gestation 
of Sham or mRUPP mice treated with MZe786 or control. MAP was significantly 
upregulated in mRUPP mice (n=15) compared to Sham (n=15). MZe786 (n=7) effectively 
reduced the increase in MAP induced by mRUPP. (B) Representative H&E images of 
kidney from different groups (scale bar represents 50µm). Sham kidney section showed 
normal renal cortex and glomerular tufts. mRUPP group showed marked kidney damage 
including glomerular degeneration with absence of bowman’s capsular space, 
disorganised tubules, fibrosis and vascular congestion. MZe786 treated Sham and 
mRUPP showed architecture similar to Sham, n=6. (C) The graph shows the scoring of the 
pathological changes, n=6. (D) Urine levels of KIM-1 in Sham or mRUPP mice treated with 
MZe786 or control. mRUPP induced significantly high levels of KIM-1. MZe786 treated 
mice showed significant reduction in KIM-1 levels, n=6. Data expressed as mean (±SEM) 
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and analysed by 2-way ANOVA. Clear circles represent group that received drug career 
and black squares represent group that received MZe786. 
 
Figure 3. H2S-releasing molecule, MZe786 reduced renal oxidative stress in mRUPP 
model. (A) Nitrotyrosine levels, a footprint of peroxynitrite production, in kidneys of 
different groups are shown (scale bar represents 50µm). The nitrotyrosine levels was 
upregulated in mRUPP compared to Sham. The levels of nitrotyrosine remain unchanged 
in Sham treated with MZe786. MZe786 treatment significantly decreased nitrotyrosine 
production in mRUPP kidneys. (B) Graph showing quantification of nitrotyrosine 
staining.Data expressed as mean (±SEM) and analysed by 2-way ANOVA, n=4. Clear 
circles represent group that received drug career and black squares represent group that 
received MZe786. 
 
Figure 4. Fetal outcome was rescued by MZe786 in mRUPP (A) Representative 
images of uterine horn (E17.5) showing increased fetal loss in mRUPP and the rescue 
effect of MZe786 in mRUPP. (B) Live birth rate expressed as percentage in Sham and 
mRUPP treated with MZe786 or control. The live births in mRUPP (n=9) was significantly 
lower compared to Sham (n=6). Importantly MZe786 (n=8) rescued mRUPP induced 
miscarriages, significantly increasing live births. No adverse effect was seen in Sham 
treated with MZe786 (n=6). Data expressed as mean (±SEM) and analysed by 2-way 
ANOVA. Clear circles represent group that received drug career and black squares 
represent group that received MZe786. 
 
Figure 5. MZe786 reversed altered placental morphology in mRUPP model. (A) Gross 
histological assessment of placental morphology showed marked reduction of placental 
labyrinth zone (indicated by dashed lines) in mRUPP compared to Sham (scale bar 
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represents 1mm). Oral administration of MZe786 significantly reduced this structural 
alteration induced by mRUPP. Placenta of Sham mice treated with MZe786 remain 
unchanged (n=4). (B) Isolectin B4 staining of labyrinth zone showing altered vasculature in 
the mRUPP mice and rescue when treated with MZe786. (C) Graph showing the 
measurement of area of labyrinth zone using Image J software. Results are representative 
or expressed as mean (±SEM) and analysed by 2-way ANOVA, n=7. Clear circles 
represent group that received drug career and black squares represent group that 
received MZe786. 
 
Figure 6. MZe786 rescue PE phenotype in mRUPP by downregulating sFlt-1. qPCR 
data showing decreased CSE mRNA expression in mRUPPs compared to Sham (A). 
mRNA expression levels of sFlt-1 in placenta (B). ELISA data showing protein levels of 
sFlt-1 in amniotic fluid (C), and plasma (D). CSE mRNA expression was significantly 
downregulated in mRUPPs and the sFlt-1 levels were correspondingly upregulated in 
mRUPPs compared to Sham. MZe786 effectively lowered sFlt-1 expression in mRUPP 
mice. Data expressed as mean (±SEM) and analysed by 2-way ANOVA, n=6. Black bars 
represent group that received drug career and white bars represent group that received 
MZe786. 
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Research Highlights: 
• Refined mouse reduced uterine perfusion pressure (mRUPP) model 
exhibits preeclampsia symptoms 
• Mouse RUPP induces maternal hypertension, kidney injury, elevates 
circulating sFlt-1 levels and promotes nitrosative stress 
• Mouse RUPP reduces expression of the protective enzyme, placental 
cystathionine γ-lyase and causes poor fetal outcome 
• H2S releasing aspirin, MZe786, acts as an inhibitor of sFlt-1 to 
successfully prevent preeclampsia and improve fetal outcome  
• MZe786 is a novel drug with therapeutic potential to prevent 
preeclampsia 
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